Mirum Pharmaceuticals, Inc. (MIRM) Misses Q4 EPS by 155c

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q4 EPS of ($1.85), $1.55 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $99.41 million versus the consensus estimate of $95.4 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• Yatsen Holding (YSG) Reports Q2 Loss of $0.16
• Citi keeps Buy rating on Viking Holdings amid river disruption
• GitLab Inc (GTLB) Tops Q2 EPS by 7c, Beats on Revenue